Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance
2022 total revenue of $723 million, up 64% from $439 million in 2021 HEPLISAV-B® vaccine net product revenue of $126 million, representing 104% growth compared...